Revenue: As of FY2025 Q3, the actual value is USD 1.446 M, beating the estimate of USD 1.411 M.EPS: As of FY2025 Q3, the actual value is USD -4.74, missing the estimate of USD -2.7.EBIT: As of FY2025 Q3, the actual value is USD -2.289 M, beating the estimate of USD -2.735 M.<h3>Financial Metrics by Segment</h3><h4>Segment Revenue</h4><ul><li>Diagnostic R&amp;D: $0 for the three months ended September 30, 2025, compared to $1,731 for the same period in 2024. $0 for the nine months ended September 30, 2025, compared to $8,654 for the same period in 2024.</li><li>Laboratory Services: $1,446,066 for the three months ended September 30, 2025, compared to $2,348,655 for the same period in 2024. $4,569,146 for the nine months ended September 30, 2025, compared to $7,145,775 for the same period in 2024.</li></ul><h4>Operational Metrics</h4><ul><li>Net Loss: -$5,051,084 for the three months ended September 30, 2025, compared to -$2,000,840 for the same period in 2024. -$11,772,288 for the nine months ended September 30, 2025, compared to -$6,072,934 for the same period in 2024.</li><li>Total Operating Expenses: $3,738,912 for the three months ended September 30, 2025, compared to $4,324,250 for the same period in 2024. $12,004,691 for the nine months ended September 30, 2025, compared to $13,161,321 for the same period in 2024.</li><li>Direct Costs and Expenses: $942,211 for the three months ended September 30, 2025, compared to $1,440,158 for the same period in 2024. $3,326,673 for the nine months ended September 30, 2025, compared to $4,421,309 for the same period in 2024.</li><li>Research and Development: $330,589 for the three months ended September 30, 2025, compared to $274,497 for the same period in 2024. $1,009,347 for the nine months ended September 30, 2025, compared to $1,070,569 for the same period in 2024.</li><li>Clinical Development: $143,311 for the three months ended September 30, 2025, compared to $93,705 for the same period in 2024. $410,943 for the nine months ended September 30, 2025, compared to $194,127 for the same period in 2024.</li><li>Selling, General and Administrative: $2,209,441 for the three months ended September 30, 2025, compared to $2,364,592 for the same period in 2024. $6,876,551 for the nine months ended September 30, 2025, compared to $7,023,311 for the same period in 2024.</li><li>Depreciation and Amortization: $113,360 for the three months ended September 30, 2025, compared to $151,298 for the same period in 2024. $381,177 for the nine months ended September 30, 2025, compared to $452,005 for the same period in 2024.</li></ul><h4>Cash Flow</h4><ul><li>Net Cash Used in Operating Activities: -$6,769,279 for the nine months ended September 30, 2025, compared to -$5,587,634 for the same period in 2024.</li><li>Net Cash Used in Investing Activities: -$60,567 for the nine months ended September 30, 2025, compared to -$79,082 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $13,393,750 for the nine months ended September 30, 2025, compared to $3,601,726 for the same period in 2024.</li></ul><h4>Unique Metrics</h4><ul><li>CyPath® Lung Testing Revenue: Increased approximately 86% to $619,000 for the nine months ended September 30, 2025, compared to $332,000 for the same period in 2024.</li><li>Sales of CyPath® Lung: Reached a record high in the third quarter of 2025, representing a 95% increase over the previous quarter.</li></ul><h4>Future Outlook and Strategy</h4><ul><li>Core Business Focus: The company plans to continue advancing the development of its flow cytometry+AI platform for diagnostic tests targeted at COPD and asthma. It also aims to expand the commercialization of CyPath® Lung as an LDT under CAP/CLIA guidelines and potentially seek FDA clearance for broader market expansion.</li><li>Non-Core Business: The company intends to seek strategic partners to develop its therapeutic discoveries, which could result in broad-spectrum cancer treatments in the future.</li><li>Priority: Emphasis on raising additional capital through equity or debt securities, strategic relationships, or grants to support future operations and commercialization efforts.</li></ul>

bioAffinity Tech | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 1.446 M